Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3
NCT ID: NCT04263922
Last Updated: 2024-07-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
466 participants
INTERVENTIONAL
2020-06-30
2026-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy
NCT05839314
Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients
NCT06796660
Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Impairment Renal Functions
NCT04142970
A Trial of HR19042 Capsule in Healthy Chinese Subjects
NCT04887532
Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis
NCT02063100
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Huaiqihuang group
Combine the use of Huaiqihuang granules and Valsartan capsule simulant.
Huaiqihuang granules
Huaiqihuang granules, 2 bags at a time, 3 times a day. Valsartan capsule simulant, 80mg at a time, once a day. Oral administration.
Valsartan Group
Combine the use of Valsartan capsule and Huaiqihuang granules simulant.
Valsartan capsule
Valsartan capsule, 80mg at a time, once a day. Huaiqihuang granules simulant, 2 bags at a time, 3 times a day. Oral administration.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Huaiqihuang granules
Huaiqihuang granules, 2 bags at a time, 3 times a day. Valsartan capsule simulant, 80mg at a time, once a day. Oral administration.
Valsartan capsule
Valsartan capsule, 80mg at a time, once a day. Huaiqihuang granules simulant, 2 bags at a time, 3 times a day. Oral administration.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female, 18≤age≤65
3. Blood pressure can be effectively controlled at or below 140/90mmHg
4. 30mL/（min.1.73m2）≤ eGFR\<60mL/（min.1.73m2）
5. 24-hour urine protein ration ≤ 2.0g/24h
6. The participants must be capable of understanding and comply with the protocol and sign a written informed consent document
Exclusion Criteria
2. Exposure to corticosteroids, immunosuppressors, tripterygium glycosides, ARBs or ACEIs, without a two weeks washout period
3. Blood pressure \< 90/60 mmHg
4. Serum potassium \> 5.5 mmol/L
5. Serum albumin \< 30g/L
6. Unilateral or bilateral renal artery stenosis
7. Pregnant or lactating women, and participants (including males) who were unable or unwilling to take adequate contraception during the study period
8. Having comorbidities that affect the progression of primary glomerulonephritis (including but not limited to Malignant tumors, Systemic autoimmune diseases, Liver cirrhosis, Diabetes, and Gout)
9. Allergic to the Huaiqihuang Granule or valsartan
10. Participating in another clinical trial
11. Investigators do not think it suitable for a participant to join this study
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Huazhong University of Science and Technology
OTHER
LinkDoc Technology (Beijing) Co. Ltd.
INDUSTRY
The First Affiliated Hospital of Dalian Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hongli Lin, MD
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of Dalian Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Hospital
Beijing, Beijing Municipality, China
Lanzhou University Second Hospital
Lanzhou, Gansu, China
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The First Affiliated Hospital of Hebei North University
Zhangjiakou, Hebei, China
The 2nd Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Henan Provincial people's Hospital
Zhengzhou, Henan, China
Xiangya Hospital of Central South University
Changsha, Hunan, China
The first affiliated Hospital of Baotou Medical College of Inner Mongolia University of Science and Technology
Baotou, Inner Mongolia, China
Affiliated Hospital of Chifeng University
Chifeng, Inner Mongolia, China
Changzhou NO.2 People's Hospital
Changzhou, Jiangsu, China
Jiangsu Province Hospital of Chinese Medicine
Nanjing, Jiangsu, China
The First Bethune Hospital of Jilin University
Changchun, Jilin, China
The Second Hospital of Jilin University
Changchun, Jilin, China
Anshan Central Hospital
Anshan, Liaoning, China
Anshan Shuangshan Hospital
Anshan, Liaoning, China
Ansteel Group General Hospital
Anshan, Liaoning, China
Benxi Iron and Steel General Hospital of Liaoning Health Industry Group
Benxi, Liaoning, China
The First Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China
Dalian Ruikaier Nephropathy Hospital
Dalian, Liaoning, China
Shengjing Hospital of China Medical University( Huaxiang Area)
Shenyang, Liaoning, China
The First Hospital of China Medical University
Shenyang, Liaoning, China
Central Hospital affiliated to Shenyang Medical College
Shenyang, Liaoning, China
Shengjing Hospital of China Medical University (Nanhu Area)
Shenyang, Liaoning, China
Yingkou Central Hospital
Yingkou, Liaoning, China
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China
Qilu Hospital of Shandong University
Jinan, Shandong, China
The Sixth People's Hospital affiliated to Shanghai Jiaotong University
Shanghai, Shanghai Municipality, China
Xinhua Hospital Affiliated to Shanghai Jiaotong University School of medicine
Shanghai, Shanghai Municipality, China
Second Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
Shanxi Provincial people's Hospital
Taiyuan, Shanxi, China
The Second Hospital of Tianjin Medical University
Tianjin, Tianjin Municipality, China
Kunming Yan'an Hospital
Kunming, Yunnan, China
Zhejiang Provincial people's Hospital
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Dajun Liu
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HQH-201911
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.